** Shares of healthcare company Organon OGN.N rise 11.2% to $16.34

** The developer of drugs for women's health and biosimilars posts Q4 adjusted profit of 90 cents per share vs analysts' average estimate of 87 cents per share - data compiled by LSEG

** Q4 revenue at $1.59 billion, in line with the estimate

** "We expect a slightly positive stock reaction on Q4 EPS beat and better EBITDA guidance, as the revenue guidance was materially impacted by FX," says brokerage BNP Paribas Exane

** Company forecasts 2025 revenue in the range of $6.13 billion to $6.33 billion, below analysts' estimate of $6.47 billion

** OGN shares down ~3% in the last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))